| 臺大學術典藏 |
2022-09-07T06:50:01Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; Chen C.-C.; YI-CHIA LEE; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2022-09-07T06:49:53Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; Chen C.-C.; Bair M.-J.; Chang C.-Y.; YI-CHIA LEE; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-09-07T06:49:52Z |
Faecal haemoglobin concentration influences risk prediction of interval cancers resulting from inadequate colonoscopy quality: Analysis of the Taiwanese Nationwide Colorectal Cancer Screening Program
|
Chiu S.Y.-H.; Chuang S.-L.; Chen S.L.-S.; Yen A.M.-F.; Fann J.C.-Y.; Chang D.-C.; YI-CHIA LEE; Wu M.-S.; Chou C.-K.; Hsu W.-F.; Chiou S.-T.; Chiu H.-M. |
| 臺大學術典藏 |
2022-09-07T06:49:46Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; Chen C.-C.; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; YI-CHIA LEE; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-09-07T06:49:45Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; YI-CHIA LEE; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-09-07T06:49:45Z |
Rolling-out Screening Volume Affecting Compliance Rate and Waiting Time of FIT-based Colonoscopy
|
Jen H.-H.; Hsu C.-Y.; Chen S.L.-S.; Yen A.M.-F.; Chiu S.Y.-H.; Fann J.C.-Y.; YI-CHIA LEE; Wu M.-S.; Hsu W.-F.; Peng S.-M.; Chen H.-H.; Chiu H.-M. |
| 臺大學術典藏 |
2022-09-07T06:49:43Z |
Effects of screening and universal healthcare on long-term colorectal cancer mortality
|
YI-CHIA LEE; Hsu C.-Y.; Chen S.L.-S.; Yen A.M.-F.; Chiu S.Y.-H.; Fann J.C.-Y.; Chuang S.-L.; Hsu W.-F.; Chiang T.-H.; Chiu H.-M.; Wu M.-S.; Chen H.-H. |
| 臺大學術典藏 |
2022-09-07T06:49:41Z |
Time to Colonoscopy and Risk of Colorectal Cancer in Patients With Positive Results From Fecal Immunochemical Tests
|
YI-CHIA LEE; Fann J.C.-Y.; Chiang T.-H.; Chuang S.-L.; Chen S.L.-S.; Chiu H.-M.; Yen A.M.-F.; Chiu S.Y.-H.; Hsu C.-Y.; Hsu W.-F.; Wu M.-S.; Chen H.-H. |
| 臺大學術典藏 |
2022-09-07T06:49:40Z |
The Rise of Colorectal Cancer in Asia: Epidemiology, Screening, and Management
|
Onyoh E.F.; Hsu W.-F.; Chang L.-C.; YI-CHIA LEE; Wu M.-S.; Chiu H.-M. |
| 臺大學術典藏 |
2022-09-07T06:49:39Z |
Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized controlled trial
|
Chen C.-C.; Luo J.-C.; Fang Y.-J.; Lee J.-Y.; Kuo C.-C.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Bair M.-J.; Chen P.-Y.; Chou C.-K.; Chen C.-Y.; Chang C.-Y.; Hsu Y.-C.; Tseng C.-H.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Hsieh C.-L.; Chen M.-J.; Shun C.-T.; Liu T.-Y.; YI-CHIA LEE; Liou, J.-M.; Wu, M.-S.; and for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-09-07T06:49:37Z |
Classifying interval cancers as false negatives or newly occurring in fecal immunochemical testing
|
Hsu W.-F.; Hsu C.-Y.; Yen A.M.-F.; Chen S.L.-S.; Chiu S.Y.-H.; Fann J.C.-Y.; YI-CHIA LEE; Chiu H.-M.; Chen H.-H. |
| 臺大學術典藏 |
2022-09-07T06:49:34Z |
Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme
|
Peng S.-M.; Hsu W.-F.; Wang Y.-W.; Lin L.-J.; Yen A.M.-F.; Chen L.-S.; YI-CHIA LEE; Wu M.-S.; Chen T.H.-H.; Chiu H.-M. |
| 臺大學術典藏 |
2022-09-07T06:49:33Z |
Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers
|
Chiu H.-M.; Jen G.H.-H.; Wang Y.-W.; Fann J.C.-Y.; Hsu C.-Y.; Jeng Y.-C.; Yen A.M.-F.; Chiu S.Y.-H.; Chen S.L.-S.; Hsu W.-F.; YI-CHIA LEE; Wu M.-S.; Wu C.-Y.; Jou Y.-Y.; Chen T.H.-H. |
| 臺大學術典藏 |
2022-09-07T06:49:32Z |
Risk of colonoscopy-related complications in a fecal immunochemical test-based population colorectal cancer screening program
|
Hsu W.-F.; Chang C.-Y.; Chang C.-C.; Chang L.-C.; Chen C.-H.; Lin C.-C.; Lin Y.-M.; Lee C.-L.; Wu H.-Y.; Lee H.-C.; YI-CHIA LEE; Su M.-Y.; Lin L.-J.; Chia S.-L.; Wu M.-S.; Chiu H.-M. |
| 臺大學術典藏 |
2022-09-06T07:42:59Z |
Predictors of in-hospital mortality after acute variceal bleeding in patients with hepatocellular carcinoma and concurrent main portal vein thrombosis
|
Han M.-L.; Chen C.-C.; Kuo S.-H.; Hsu W.-F.; Liou J.-M.; MING-SHIANG WU; Wang H.-P. |
| 臺大學術典藏 |
2022-09-06T07:42:58Z |
Carbon dioxide insufflation can significantly reduce toilet use after colonoscopy: A double-blind randomized controlled trial
|
Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Lai H.-H.; Chen M.-K.; Chang L.-C.; Tu C.-H.; Chou C.-K.; Wang H.-P.; MING-SHIANG WU; Chiu H.-M. |
| 臺大學術典藏 |
2022-07-20T06:33:42Z |
Clinical outcomes of intravitreal methotrexate injection protocol with a reduced initial frequency for intraocular lymphoma
|
Hsu C.-J.; Hou H.-A.; Lin C.-P.; Lee Y.-J.; Hsu W.-F.; PO-TING YEH |
| 臺大學術典藏 |
2022-04-21T06:50:22Z |
Rolling-out Screening Volume Affecting Compliance Rate and Waiting Time of FIT-based Colonoscopy
|
Jen H.-H.; Hsu C.-Y.; Chen S.L.-S.; Yen A.M.-F.; Chiu S.Y.-H.; Fann J.C.-Y.; Lee Y.-C.; Wu M.-S.; Hsu W.-F.; Peng S.-M.; Chen, Tony Hsiu Hsi; Chiu H.-M. |
| 臺大學術典藏 |
2022-04-21T06:50:19Z |
Effects of screening and universal healthcare on long-term colorectal cancer mortality
|
Lee Y.-C.; Hsu C.-Y.; Chen S.L.-S.; Yen A.M.-F.; Chiu S.Y.-H.; Fann J.C.-Y.; Chuang S.-L.; Hsu W.-F.; Chiang T.-H.; Chiu H.-M.; Wu M.-S.; Chen, Tony Hsiu Hsi |
| 臺大學術典藏 |
2022-04-21T06:50:16Z |
Time to Colonoscopy and Risk of Colorectal Cancer in Patients With Positive Results From Fecal Immunochemical Tests
|
Lee Y.-C.; Fann J.C.-Y.; Chiang T.-H.; Chuang S.-L.; Chen S.L.-S.; Chiu H.-M.; Yen A.M.-F.; Chiu S.Y.-H.; Hsu C.-Y.; Hsu W.-F.; Wu M.-S.; Chen, Tony Hsiu Hsi |
| 臺大學術典藏 |
2022-04-21T06:50:12Z |
Sampling-based Markov regression model for multistate disease progression: Applications to population-based cancer screening program
|
Hsu C.-Y.; Hsu W.-F.; Yen A.M.-F.; Chen, Tony Hsiu Hsi |
| 臺大學術典藏 |
2022-04-21T06:50:10Z |
Classifying interval cancers as false negatives or newly occurring in fecal immunochemical testing
|
Hsu W.-F.; Hsu C.-Y.; Yen A.M.-F.; Chen S.L.-S.; Chiu S.Y.-H.; Fann J.C.-Y.; Lee Y.-C.; Chiu H.-M.; Chen, Tony Hsiu Hsi |
| 臺大學術典藏 |
2022-04-21T06:50:05Z |
Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme
|
Peng S.-M.; Hsu W.-F.; Wang Y.-W.; Lin L.-J.; Yen A.M.-F.; Chen L.-S.; Lee Y.-C.; Wu M.-S.; Chen, Tony Hsiu Hsi; Chiu H.-M. |
| 臺大學術典藏 |
2022-04-21T06:50:04Z |
Mitigating the impact of COVID-19 on colorectal cancer screening: Organized service screening perspectives from the Asia-Pacific region
|
Chiu H.-M.; Su C.-W.; Hsu W.-F.; Jen G.H.-H.; Hsu C.-Y.; Chen S.L.-S.; Chen, Tony Hsiu Hsi |
| 臺大學術典藏 |
2022-04-21T06:50:03Z |
Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers
|
Chiu H.-M.; Jen G.H.-H.; Wang Y.-W.; Fann J.C.-Y.; Hsu C.-Y.; Jeng Y.-C.; Yen A.M.-F.; Chiu S.Y.-H.; Chen S.L.-S.; Hsu W.-F.; Lee Y.-C.; Wu M.-S.; Wu C.-Y.; Jou Y.-Y.; Chen, Tony Hsiu Hsi |
| 臺大學術典藏 |
2022-03-22T08:31:24Z |
Exosomes - Potential for Blood-Based Marker in Alzheimer’s Disease
|
Li C.-C;Hsu W.-F;Wo A.M.; Li C.-C; Hsu W.-F; Wo A.M.; ANDREW WO |
| 臺大學術典藏 |
2022-03-22T08:31:23Z |
Exosomes - Potential for Blood-Based Marker in Alzheimer’s Disease
|
Li C.-C;Hsu W.-F;Wo A.M.; Li C.-C; Hsu W.-F; Wo A.M.; ANDREW WO |
| 臺大學術典藏 |
2022-03-22T08:28:21Z |
Exosomes - Potential for Blood-Based Marker in Alzheimer’s Disease
|
Li C.-C;Hsu W.-F;Wo A.M.; Li C.-C; Hsu W.-F; Wo A.M.; ANDREW WO |
| 臺大學術典藏 |
2022-02-23T02:19:44Z |
Primary endovascular intervention for acute mesenteric ischemia performed by interventional cardiologists – A single center experience
|
Chen T.-Y.; Wu C.-H.; Hsu W.-F.; Lin L.; Wang R.-H.; Lai C.-L.; Tsai K.-C.; Keng L.-T.; CHIH-CHENG WU; Hsieh M.-Y. |
| 臺大學術典藏 |
2022-02-22T03:37:13Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; PING-HUEI TSENG; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:46:52Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; CHIEN-CHUAN CHEN; Lee Y.-C.; Chen M.-J.; CHIEN-CHUAN CHEN; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-18T08:46:50Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; CHIEN-CHUAN CHEN; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; CHIEN-CHUAN CHEN; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:46:49Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; Wu M.-S.; CHIEN-CHUAN CHEN; CHIEN-CHUAN CHEN; Fang Y.-J.; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:46:45Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; CHIEN-CHUAN CHEN; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; CHIEN-CHUAN CHEN; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:26:07Z |
Predictors of in-hospital mortality after acute variceal bleeding in patients with hepatocellular carcinoma and concurrent main portal vein thrombosis
|
Han M.-L.; CHIEH-CHANG CHEN; Kuo S.-H.; Hsu W.-F.; Liou J.-M.; Wu M.-S.; Wang H.-P. |
| 臺大學術典藏 |
2022-02-18T08:26:06Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; CHIEH-CHANG CHEN; Lee Y.-C.; Chen M.-J.; CHIEH-CHANG CHEN; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-18T08:26:04Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; CHIEH-CHANG CHEN; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; CHIEH-CHANG CHEN; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:26:03Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; Wu M.-S.; CHIEH-CHANG CHEN; CHIEH-CHANG CHEN; Fang Y.-J.; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:26:02Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:26:01Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; CHIEH-CHANG CHEN; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; CHIEH-CHANG CHEN; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:25:58Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; CHIEH-CHANG CHEN; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T08:25:57Z |
Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized controlled trial
|
CHIEH-CHANG CHEN; Luo J.-C.; Fang Y.-J.; Lee J.-Y.; Kuo C.-C.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Bair M.-J.; Chen P.-Y.; Chou C.-K.; Chen C.-Y.; Chang C.-Y.; Hsu Y.-C.; Tseng C.-H.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Hsieh C.-L.; Chen M.-J.; Shun C.-T.; Liu T.-Y.; Lee§ Y.-C.; Liou§ J.-M.; Wu§ M.-S.; and for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:51Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; Chen C.-C.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; YU-JEN FANG; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-14T06:28:49Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; YU-JEN FANG; Chen C.-C.; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:48Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; Wu M.-S.; Chen C.-C.; Chen C.-C.; YU-JEN FANG; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:48Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; Chen C.-C.; YU-JEN FANG; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:47Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; YU-JEN FANG; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:46Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; Chen C.-C.; Chang C.-M.; YU-JEN FANG; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chen C.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:45Z |
Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized controlled trial
|
Chen C.-C.; Luo J.-C.; YU-JEN FANG; Lee J.-Y.; Kuo C.-C.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Bair M.-J.; Chen P.-Y.; Chou C.-K.; Chen C.-Y.; Chang C.-Y.; Hsu Y.-C.; Tseng C.-H.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Hsieh C.-L.; Chen M.-J.; Shun C.-T.; Liu T.-Y.; Lee§ Y.-C.; Liou§ J.-M.; Wu§ M.-S.; and for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-01-25T07:24:22Z |
Risk of colonoscopy-related complications in a fecal immunochemical test-based population colorectal cancer screening program
|
Hsu W.-F.; Chang C.-Y.; Chang C.-C.; Chang L.-C.; Chen C.-H.; Lin C.-C.; Lin Y.-M.; Lee C.-L.; Wu H.-Y.; Lee H.-C.; Lee Y.-C.; Su M.-Y.; Lin L.-J.; Chia S.-L.; MING-SHIANG WU; Chiu H.-M. |
